Boundless Bio, Inc.

BOLD

$2.88

+0.35%

2026-09-04 12:43:38 EDT+$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients ...

Price Action of BOLD

$2.88

+0.35%+$0.01

High—

Low—

52W High-9.0%

Rel. vol—

Interval

Range2.3h

Volume—SMA5SMA10

—

Boundless Bio, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to addressing the significant unmet needs of patients with oncogene amplified cancers. The company was incorporated in 2018 and originally operated as Pretzel Therapeutics, Inc. before rebranding to Boundless Bio in July 2019. Its core scientific ...Boundless Bio, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to addressing the significant unmet needs of patients with oncogene amplified cancers. The company was incorporated in 2018 and originally operated as Pretzel Therapeutics, Inc. before rebranding to Boundless Bio in July 2019. Its core scientific focus is on extrachromosomal DNA (ecDNA), which are circular DNA molecules that drive tumorigenesis and drug resistance by amplifying oncogenes. Boundless Bio is the first company to specifically target ecDNA, positioning itself as a leader in this emerging field. The company's lead product candidate, BBI-355, is an orally administered inhibitor of checkpoint kinase 1 (CHK1), which is currently in Phase 1/2 clinical trials for patients with oncogene amplified cancers. Additionally, BBI-825, an oral inhibitor of ribonucleotide reductase (RNR), is also in Phase 1/2 development for cancers exhibiting resistance gene amplifications. A third program, ecDTx 3, targets a kinesin essential for the cellular segregation of ecDNA during mitosis. This pipeline reflects the company's commitment to developing a next wave of cancer medicines that go beyond traditional targeted therapies. As a public company listed on NASDAQ under the ticker BOLD since its IPO on March 28, 2024, Boundless Bio has a market capitalization of approximately $61.8 million as of the latest data, with a stock price of $2.75. The company has 28 full-time employees and operates in the biotechnology sector. Financially, it has not yet generated revenue (price-to-sales ratio is zero), and its financial metrics show significant investment in R&D and operating expenses, leading to negative net income and cash flow from operations, which is typical for a clinical-stage biotech. The balance sheet shows a current ratio of 9.481, indicating strong liquidity, and no long-term debt, reflecting a healthy cash position to fund ongoing trials. Key personnel include CEO and President Zachary Hornby, who also serves as a director, and co-founders such as Dr. Paul Mischel, a scientific co-founder, and Jonathan Lim, among others. The company's leadership team brings deep precision oncology and business expertise. Boundless Bio has attracted significant venture funding, including a $100 million Series C round, and continues to advance its pipeline with the goal of delivering innovative therapies to patients suffering from intractable cancers. With its focus on ecDNA, the company aims to unlock a new paradigm in cancer therapeutics, addressing the root causes of oncogene amplification and drug resistance.ExpandCollapse

Founded

2018

Employees

CEO

Zachary Hornby

Full Name

Boundless Bio, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-70.89%

Market Cap

$0.07B

Current Ratio

9.48

WACC

5.54%

ROIC

-97.02%

Contact Information

https://boundlessbio.com

858 766 9912

10955 Alexandria Way, San Diego, CA 92121

Key Metrics of BOLD

Snapshot

Latest / TTM · 6 periods

Market Cap

$65.51M

ROCE

-103.1%

EV / EBITDA

-0.75x

-59.1% YoY

FCF Yield

-88.3%

+87.7% YoY

Cash Conversion Cycle

-2023.5d

Current Ratio

9.48

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of BOLD

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-1.00x

n/a

Debt / Equity

0.00

n/a

Current Ratio

9.48

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of BOLD

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.56 · Revenue $0.00 · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.32 · Revenue $0.00 · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-2.53 · Revenue $0.00 · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.70 · Revenue $0.00 · 1 analysts

Recent history

Aug 7, 2026
Q2 FY2026 · Results reported
EPS $-1.06 · Revenue $0.00
View filing
May 8, 2026
Q1 FY2026 · Results reported
EPS $-0.60 · Revenue $0.00
View filing
Mar 9, 2026
FY2025 · Annual results
EPS $-2.60 · Revenue $0.00
View filing
Nov 5, 2025
Q3 FY2025 · Results reported
EPS $-0.62 · Revenue $0.00
View filing
Aug 5, 2025
Q2 FY2025 · Results reported
EPS $-0.70 · Revenue $0.00
View filing
May 9, 2025
Q1 FY2025 · Results reported
EPS $-0.71 · Revenue $0.00
View filing

Financial Statements of BOLD

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-58.2M	+11.0%	-74.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-47.2M	+25.5%	-40.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	49.7%	+57.2%	-100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	8.74x	-53.9%	-4.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$157.1M	-23.9%	-47.7%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-2.60 vs -2.47	-5.3%	-1.06 vs -1.06	0.0%
Revenue Surprise	—	—	—	—

Insider Transactions of BOLD

Acquisitions (A)

Since Jul 9, 2026

Disposals (D)

Since Jul 9, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 26, 2026	TANG KEVIN	10 percent owner	Common Stock	D	18,300	$2.97
Jul 21, 2026	TANG KEVIN	10 percent owner	Common Stock	A	2,975	$2.44
Jul 20, 2026	TANG KEVIN	10 percent owner	Common Stock	A	1,623	$2.44
Jul 17, 2026	TANG KEVIN	10 percent owner	Common Stock	A	265	$2.44
Jul 16, 2026	TANG KEVIN	10 percent owner	Common Stock	A	18,491	$2.44

Leadership Team of BOLD

7 executives

Name	Title	Compensation	Gender	Year Born	Status
Zachary Hornby	Chief Executive Officer, President & Director	USD 974,855	Male	1979	Active
Robert C. Doebele	Chief Medical Officer	USD 690,275	—	1971	Active
Christian Hassig	Chief Scientific Officer	USD 673,000	—	1972	Active
David Hinkle	Senior Vice President of Finance, Controller & Corporate Treasurer	—	Male	1962	Active
Amy Berkley	Senior Vice President of Program Team	—	Female	—	Active
Meredith Wesley	Chief Human Resources Officer	—	Female	—	Active
Jessica Oien	President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary	—	Female	1971	Active

Recent News of BOLD

GlobeNewsWire7/2/2026Neutral

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

GuruFocus6/25/2026Neutral

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026

GuruFocus6/23/2026Neutral

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) PR Newswire

PRNewsWire6/23/2026Neutral

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Boundless Bio, Inc. (NASDAQ: BOLD ) related to its merger with Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.

Business Wire6/23/2026Neutral

BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.Halper Sadeh encourages Boundless Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.

Historical Employee Count of BOLD

Current

Change

-56.25%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	28	10-K	Mar 9, 2026	View
Dec 31, 2024	64	10-K	Mar 27, 2025	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Boundless Bio, Inc.